<DOC>
	<DOCNO>NCT00428610</DOCNO>
	<brief_summary>The primary objective determine whether LY573636 effective treat platinum-resistant ovarian cancer . Patients receive intravenous infusion study drug every 28 day . CT scan CA-125 test do first dose every treatment .</brief_summary>
	<brief_title>A Study Chemotherapy Treatment Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Diagnosis epithelial ovarian cancer , fallopian tube cancer , primary peritoneal cancer At least 18 year old Have receive least one 2 systemic treatment regimen contain platinum ( include regimen receive surgery cancer ) Have platinumresistant disease Have receive 2 systemic treatment regimens platinumresistant disease Serious preexist medical condition Actively receive warfarin ( Coumadin ) treatment venous thrombosis prothrombotic condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>